Study of Gecacitinib and Steroids for Acute Graft-Versus-Host Disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new pill (gecacitinib) combined with steroids as the first treatment for moderate to severe acute graft-versus-host disease after a stem cell transplant. The goal is to see if this combination works better than steroids alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have given consent.
- You had a stem cell transplant using bone marrow or stem cells from blood (not cord blood).
- You have not been on steroids for graft-versus-host disease for more than 2 days.
- You have moderate to severe acute graft-versus-host disease (as diagnosed by your doctor).
- You are able to swallow pills and can follow study visits.
- You have not had more than one stem cell transplant, and do not have uncontrolled infections or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
This trial tests a new pill called gecacitinib for people whose chronic graft-versus-host disease (a condition where donor cells attack their body after a stem cell transplant) has not gotten better with steroids. The drug aims to control the disease and help you feel better.
This trial tests a new drug, gecacitinib, for patients with moderate to severe chronic graft-versus-host disease (cGVHD) that has not improved after 2 to 5 prior treatments. It aims to see if the drug is safe and effective.
This study tests an experimental medicine called gecacitinib for people who have graft-versus-host disease (GVHD) after a stem cell transplant and whose GVHD did not improve with standard second-line treatment (ruxolitinib). The goal is to see if this new treatment can help control GVHD symptoms.
This trial tests whether a new medication called gecacitinib can prevent a common complication after a stem cell transplant for myelofibrosis. The complication, called graft-versus-host disease, happens when donor cells attack the patient's body. The drug is given before and after the transplant.
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Hear when a new aGVHD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.